Creo Medical Group (LON:CREO) Stock Crosses Below 50 Day Moving Average – Here’s Why

Creo Medical Group PLC (LON:CREO)’s stock price crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 13.90 and traded as low as GBX 13.03. Creo Medical Group shares last traded at GBX 13.44, with a volume of 166,113 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Shore Capital Group reiterated a “house stock” rating and issued a GBX 40 price target on shares of Creo Medical Group in a report on Thursday, July 23rd.

Creo Medical Group Price Performance

The stock’s 50 day moving average price is GBX 13.90 and its 200-day moving average price is GBX 13.39. The company has a quick ratio of 2.19, a current ratio of 3.22 and a debt-to-equity ratio of 8.20. The stock has a market capitalization of £65.58 million, a PE ratio of 13.50 and a beta of 1.62.

Creo Medical Group (LON:CREO) last posted its quarterly earnings results on Friday, May 22nd. The company reported GBX (0.04) EPS for the quarter. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%.The company had revenue of GBX 600 million during the quarter. As a group, equities analysts forecast that Creo Medical Group PLC will post -10.0800005 EPS for the current year.

Insider Buying and Selling

In other news, insider Craig Jonathan Gulliford purchased 6,250 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was purchased at an average price of GBX 14 per share, for a total transaction of £875. Also, insider Richard John Rees acquired 6,250 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was purchased at an average cost of GBX 14 per share, for a total transaction of £875. Company insiders own 6.92% of the company’s stock.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.